代谢组学在结直肠癌预后评估中的潜力
The Potential of Metabolomics in Colorectal Cancer Prognosis.
作者信息
Fu Chengqu, Liu Xinyi, Wang Le, Hang Dong
机构信息
Department of Epidemiology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative, Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing 211166, China.
Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
出版信息
Metabolites. 2024 Dec 15;14(12):708. doi: 10.3390/metabo14120708.
Colorectal cancer (CRC) is one of the most common cancers worldwide, posing a serious threat to human health. Metabolic reprogramming represents a critical feature in the process of tumor development and progression, encompassing alterations in sugar metabolism, lipid metabolism, amino acid metabolism, and other pathways. Metabolites hold promise as innovative prognostic biomarkers for cancer patients, which is crucial for targeted follow-up care and interventions. This review aims to provide an overview of the progress in research on metabolic biomarkers for predicting the prognosis of CRC. We also discuss the future trends and challenges in this area.
结直肠癌（CRC）是全球最常见的癌症之一，对人类健康构成严重威胁。代谢重编程是肿瘤发生发展过程中的一个关键特征，包括糖代谢、脂代谢、氨基酸代谢等途径的改变。代谢物有望成为癌症患者创新的预后生物标志物，这对于针对性的后续护理和干预至关重要。本综述旨在概述预测CRC预后的代谢生物标志物的研究进展。我们还讨论了该领域的未来趋势和挑战。
Zotero 插件